EGFR and melanoma: Currently available treatments include imatinib for KIT alterations in GIST, gefitinib, osimertinib, sotorasib, crizotinib, for alterations in EGFR, KRAS, and ALK fusion in NSCLC, PARP inhibitors, and alpelisib for BRCA1/2 and PIK3CA variants in gynecologic malignancies, and dabrafenib and trametinib for BRAF V600E in melanoma and metastatic papillary thyroid carcinoma.19, 20, 21, 22, 23, 24